Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 21, 2025; 31(35): 110370
Published online Sep 21, 2025. doi: 10.3748/wjg.v31.i35.110370
Published online Sep 21, 2025. doi: 10.3748/wjg.v31.i35.110370
From bench to bedside: Advancements in patient-derived xenografts for predicting therapy outcomes in colorectal cancer
Andrei Nicolae Ceobanu, Department of Oncology, University of Medicine and Pharmacy “Grigore T Popa”, Regional Institute of Oncology, Iasi 700115, Romania
Alexandru Florin Braniște, Department of Endocrinology, University of Medicine and Pharmacy “Grigore T Popa”, Emergency Clinical County Hospital “Saint Spiridon”, Iasi 700115, Romania
Ştefan Morărașu, Gabriel Mihail Dimofte, Department of Surgery, University of Medicine and Pharmacy “Grigore T Popa”, Regional Institute of Oncology, Iasi 700115, Romania
Author contributions: Dimofte GM conceptualized the review and outlined the structure; Ceobanu AN and Braniște AF conducted the literature search and wrote the manuscript; Dimofte GM and Morărașu Ş provided supervision and final editing; and all authors discussed the content, reviewed the manuscript, and approved the final version.
Supported by the European Union, the Romanian Government and the Health Program (Medical Applications of High-Power Lasers - Dr. LASER), cod MySMIS2021/SMIS2021+ 326475.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Alexandru Florin Braniște, MD, Department of Endocrinology, University of Medicine and Pharmacy “Grigore T Popa”, Emergency Clinical County Hospital “Saint Spiridon”, 16 University Street, Iasi 700115, Romania.
Received: June 6, 2025
Revised: June 24, 2025
Accepted: August 20, 2025
Published online: September 21, 2025
Processing time: 105 Days and 20.1 Hours
Revised: June 24, 2025
Accepted: August 20, 2025
Published online: September 21, 2025
Processing time: 105 Days and 20.1 Hours
Core Tip
Core Tip: This minireview discussed the use of patient-derived xenograft (PDX) models in mice and zebrafish and their impact on predicting treatment outcomes in patients with colorectal cancer. Each model has its own unique advantages and disadvantages that are useful in certain situations. Mouse PDX models are better suited for longer-term and in-depth studies, and zebrafish PDX models are better for chemoprofiling and short-term treatment guidance. We also discussed the applicability of these models for personalized medicine and the synergy with current biomarkers to better select treatment.